IMMUNORNASE FUSIONS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 340

80. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM. (1996)
Angiogenin single-chain immunofusions: influence of pep-
tide linkers and spacers between fusion protein domains.
Biochemistry 35, 545-553.
81. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J,
Pallesen G, et al. (1985) The expression of the Hodgkin's
disease associated antigen Ki-1 in reactive and neoplastic
lymphoid tissue: evidence that Reed-Sternberg cells and
histiocytic malignancies are derived from activated lymphoid
cells. Blood 66, 848-858.
82. Mechtersheimer G, Moller P. (1990) Expression of Ki-1 anti-
gen (CD30) in mesenchymal tumors. Cancer 66, 1732-1737.
83. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H.
(1992) Molecular cloning and expression of a new member of
the nerve growth factor receptor family that is characteristic
for Hodgkin's disease. Cell 68, 421-427.
84. Stocker M, Tur MK, Sasse S, Krussmann A, Barth S, Engert
A. (2003) Secretion of functional anti-CD30-angiogenin
immunotoxins into the supernatant of transfected 293T-cells.
Protein Expr. Purif. 28, 211-219.
85. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg
DM. (1989) Two new monoclonal antibodies, EPB-1 and
EPB-2, reactive with human lymphoma. Cancer Res. 49,
4568-4577.
86. Arndt MA, Krauss J, Vu BK, Newton DL, Rybak SM. (2005)
A dimeric angiogenin immunofusion protein mediates selec-
tive toxicity toward CD22 þ tumor cells. J. Immunother. 28,
245-251.
87. Krauss J, Arndt MA, Vu BK, Newton DL, Rybak SM. (2005)
Targeting malignant B-cell lymphoma with a humanized anti-
CD22 scFv-angiogenin immunoenzyme. Br. J. Haematol.
128, 602-609.
88. Krauss J, Exner E, Mavratzas A, Seeber S, Arndt MA. (2009)
High-level production of a humanized immunoRNase fusion
protein from stably transfected myeloma cells. Meth. Mol.
Biol. 525, 471-490.
89. Hetzel C, Bachran C, Fischer R, Fuchs H, Barth S, Stocker M.
(2008) Small cleavable adapters enhance the specific cyto-
toxicity of a humanized immunotoxin directed against CD64-
positive cells. J. Immunother. 31, 370-376.
90. Ball ED, McDermott J, Griffin JD, Davey FR, Davis R,
Bloomfield CD. (1989) Expression of the three myeloid
cell-associated immunoglobulin G Fc receptors defined by
murine monoclonal antibodies on normal bone marrow and
acute leukemia cells. Blood 73, 1951-1956.
91. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert
A. (2000) Compatible-solute-supported periplasmic expres-
sion of functional recombinant proteins under stress condi-
tions. Appl. Environ. Microbiol. 66, 1572-1579.
92. Ogata M, Fryling CM, Pastan I, FitzGerald DJ. (1992) Cell-
mediated cleavage of Pseudomonas exotoxin between
Arg279 and Gly280 generates the enzymatically active frag-
ment which translocates to the cytosol. J. Biol. Chem. 267,
25396-25401.
93. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H.
(2003) A cleavable

cytotoxicity of recombinant immunotoxins. Int. J. Cancer
103, 77-82.
94. Deonarain MP, Epenetos AA. (1995) Construction, refolding
and cytotoxicity of a scFv-seminal RNase fusion protein.
Tumor Target. 1, 177-182.
95. Deonarain MP, Epenetos AA. (1998) Design, characterization
and antitumor cytotoxicity of a panel of recombinant, mam-
malian ribonuclease-based immunotoxins. Br. J. Cancer 77,
537-546.
96. Epenetos AA, Travers P, Gatter KC, Oliver RD, Mason DY,
Bodmer WF. (1984) An immunohistological study of testic-
ular germ cell tumors using two different monoclonal anti-
bodies against placental alkaline phosphatase. Br. J. Cancer
49, 11-15.
97. Iles RK, Ind TE, Chard T. (1994) Production of placental
alkaline phosphatase (PLAP) and PLAP-like material by
epithelial germ cell and non-germ cell tumors in vitro. Br.
J. Cancer 69, 274-278.
98. Russo N, de Nigris M, Ciardiello A, Di Donato A, D'Alessio
G. (1993) Expression in mammalian cells, purification and
characterization of recombinant human pancreatic ribonucle-
ase. FEBS Lett. 333, 233-237.
99. Ishida T, Tsujisaki M, Hanzawa Y, Hirakawa T, Hinoda Y,
Imai K, et al. (1994) Significance of erbB-2 gene product as a
target molecule for cancer therapy. Scand. J. Immunol. 39,
459-466.
100. Slamon DJ, GodolphinW, Jones LA, Holt JA, Wong SG, Keith
DE, et al. (1989) Studies of the HER-2/neu proto-oncogene in
human breast and ovarian cancer. Science 244, 707-712.
101. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. (2000)
Biochemical and clinical implications of the ErbB/HER
signaling network of growth factor receptors. Adv. Cancer
Res. 77, 25-79.
102. Press MF, Cordon-Cardo C, Slamon DJ. (1990) Expression of
the HER-2/neu proto-oncogene in normal human adult and
fetal tissues. Oncogene 5, 953-962.
103. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti
P, Piccoli R, et al. (2004) A fully human antitumor immu-
noRNase selective for ErbB-2-positive carcinomas. Cancer
Res. 64, 4870-4874.
104. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio
G. (2002) A new human antitumor immunoreagent specific
for ErbB2. Clin. Cancer Res. 8, 1710-1719.
105. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Water-
house P, Crosby WL, et al. (1994) Isolation of high affinity
human antibodies directly from large synthetic repertoires.
EMBO J. 13, 3245-3260.
106. De Lorenzo C, Di Malta C, Cal ı G, Troise F, Nitsch L,
D'Alessio G. (2007) Intracellular route and mechanism of
action of ERB-hRNase, a human anti-ErbB2 anticancer
immunoagent. FEBS Lett. 581, 296-300.
107. Riccio G, Borriello M, D'Alessio G, De Lorenzo C. (2008) A
novel human antitumor dimeric immunoRNase. J. Immun-
other. 31, 440-445.
108. Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco
C, Spalletti-Cernia D, et al. (1999) A dimeric mutant of

adapter to reduce nonspecific